

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 15 DEC 2003					
ACTION See Notification of Transmittal Control Services					
Preliminary Examination Report (Form PCT/IPEA/416)					
tte (day/month/year) Priority date (day/month/year)					
08.04.2002					
International Patent Classification (IPC) or both national classification and IPC A61K31/496					
Applicant DR. REDDY'S LABORATORIES LIMITED et al.					
 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 					
g this cover sheet.					
This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).					
3. This report contains indications relating to the following items:					
novelty, inventive step and industrial applicability					
with regard to novelty, inventive step or industrial applicability; statement					
on					
pplication					
pplication					
pplication					
Date of completion of this report					
Date of completion of this report					
Date of completion of this report 11.12.2003					
Date of completion of this report 11.12.2003					

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US03/10708

I. Basi	of the	report
---------	--------	--------

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Description, Pages					
	1-12		as originally filed			
	Olaima Numbara					
	Claims, Numbers 1-20		as originally filed			
With regard to the language, all the elements marked above were available or furnished to this Author language in which the international application was filed, unless otherwise indicated under this item.						
	The	ese elements were av	ailable or furnished to this Authority in the following language: , which is:			
		the language of a tra	anslation furnished for the purposes of the international search (under Rule 23.1(b)).			
		the language of publ	lication of the international application (under Rule 48.3(b)).			
		the language of a tra Rule 55.2 and/or 55.	anslation furnished for the purposes of international preliminary examination (under 3).			
3.	Witl inte	eotide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:				
		contained in the inte	rnational application in written form.			
		filed together with the	e international application in computer readable form.			
		furnished subsequer	ntly to this Authority in written form.			
		furnished subsequer	ntly to this Authority in computer readable form.			
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.				
		The statement that the listing has been furnitude.	he information recorded in computer readable form is identical to the written sequence ished.			
4.	The	amendments have re	esulted in the cancellation of:			
		the description,	pages:			
		the claims,	Nos.:			
		the drawings,	sheets:			
5.		This report has been been considered to g	established as if (some of) the amendments had not been made, since they have go beyond the disclosure as filed (Rule 70.2(c)).			
		(Any replacement sh report.)	neet containing such amendments must be referred to under item 1 and annexed to this			
6.	Add	dditional observations, if necessary:				



International application No.

PCT/US03/10708

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims No:

Claims

Inventive step (IS)

Yes: Claims

No:

Claims

1-20

1-20

Industrial applicability (IA)

Yes: Claims

1-20

No: Claims

see separate sheet

2. Citations and explanations

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: US-A-4980470 D2: EP-A-0805156

D3: US-A-4997943

Novelty (Article 33(2) PCT)

None of D1-D3 discloses an anhydrous crystalline form of gatifloxacin.

Inventive Step (Article 33(3) PCT)

D1-D3 disclose crystalline forms of the gatifloxacin hemihydrate, sesquihydrate and the hydrochloride salt.

The problem of the invention was the provision of new crystalline forms of gatifloxacin.

None of D1-D3 anticipates or suggests the preparation of an anhydrous crystalline form of gatifloxacin. The present invention is therefore based on an inventive step.